Prima BioMed Ltd. (PBMD) Upgraded to “Hold” at Zacks Investment Research
According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “
A number of other research analysts also recently weighed in on the stock. Maxim Group restated a buy rating on shares of Prima BioMed in a report on Wednesday, June 8th. FBR & Co restated an outperform rating and set a $6.00 price target on shares of Prima BioMed in a report on Friday, July 15th. Roth Capital restated a buy rating and set a $6.00 price target on shares of Prima BioMed in a report on Friday, August 26th. Finally, HC Wainwright restated a buy rating on shares of Prima BioMed in a report on Wednesday, June 22nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $4.20.
Prima BioMed (NASDAQ:PBMD) traded down 0.562% during trading on Thursday, reaching $0.885. The company had a trading volume of 12,446 shares. The company’s 50-day moving average is $0.87 and its 200 day moving average is $0.95. Prima BioMed has a 52 week low of $0.72 and a 52 week high of $1.54. The firm’s market capitalization is $60.82 million.
About Prima BioMed
Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.
Receive News & Stock Ratings for Prima BioMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd. and related stocks with our FREE daily email newsletter.